ATARA BIO®

ECTRIMS
Corporate Presentation

October 13, 2021

Nasdaq: ATRA

Forward-Looking Statements

This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, product candidates, correspondence with regulatory authorities, regulatory submissions, regulatory approvals, the initiation, timing, progress and results of preclinical studies and clinical trials and our research and development programs, ability to sell, manufacture or otherwise commercialize our product candidates, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, any royalty payments, and our ability to obtain and maintain intellectual property protection for our product candidates, are forward-looking statements of Atara Biotherapeutics, Inc. ("Atara" or the "Company"). These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "predict," "plan," "expect" or the negative or plural of these words or similar expressions. These forward-looking statements are subject to risks and uncertainties, including those discussed in Atara's filings with the Securities and Exchange Commission (SEC), including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings and in the documents incorporated by reference therein. These risks and uncertainties include, without limitation, risks and uncertainties associated with the costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success; the characteristics, and potential safety and efficacy of ATA188; translational and biomarker data for ATA188, including magnetization transfer ratio (MTR) data and MTR's potential link with remyelination; data from, and the timing and progress of clinical trials of ATA188; Atara's ability to successfully advance the development of ATA188; the potential market opportunity for a therapy to treat progressive multiple sclerosis; and the COVID-19 pandemic, which may significantly impact (i) our business, research, clinical development plans and operations, including our operations in South San Francisco and Southern California and at our clinical trial sites, as well as the business or operations of our third-party manufacturer, contract research organizations or other third parties with whom we conduct business, (ii) our ability to access capital, and (iii) the value of our common stock; and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Atara's own internal estimates and research. While Atara believes these third-party studies, publications, surveys and other data to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of Atara's internal estimates or research, and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.

ATARA BIO®



Introduction

Pascal Touchon, President and Chief Executive Officer

ATARA BIO®

Atara: A Differentiated Approach to Allogeneic Cell Therapy

EBV-Targeting T-Cell Products: Tab-cel® and ATA188

Healthy Donor Cells → *manufacturing* → EBV T-Cell



- ✓ Minimal HLA matching needed
- ✓ Designed to target root cause of EBV-driven diseases
- ✓ Favorable safety profile
- ✓ Robust manufacturing process
- ✓ No gene editing of the TCR

Engineered Oncology Products: Next-gen CAR T or TCR T

Next-Gen CAR Technologies

Gamma retrovirus vector → Off-the-Shelf CAR T or TCR T



- ✓ Retains beneficial features of EBV T-cell with no gene editing of TCR
- ✓ CAR-targeted activity and durability
- ✓ Can be modified to express engineered receptors to armor CAR T for solid tumors

ATARA BIO®

EBV = Epstein-Barr Virus; HLA = Human Leukocyte Antigen; CAR = Chimeric Antigen Receptor; TCR = T-cell Receptor



Updated Open-label Extension Clinical Data and New Magnetization Transfer Ratio Imaging Data from a Phase I Study of ATA188, an Off-the-shelf, Allogeneic Epstein–Barr Virus Targeted T-cell Immunotherapy for Progressive Multiple Sclerosis

Bar-Or A,[1] Pender MP,[2] Hodgkinson SJ,[3,4] Broadley S,[5] Lindsey JW,[6] Ioannides ZA,[2] Bagert B,[7] Gamelin L,[8] Liu E,[8] Ye W,[8] Willmer J,[8] Arnold DL[9,10]

[1]Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; [2]The University of Queensland, Brisbane, Australia; [3]University of New South Wales, Sydney, Australia; [4]Liverpool Hospital, Liverpool, Australia; [5]Griffith University, Southport, Australia; [6]University of Texas Health Science Center at Houston, Houston, TX, USA; [7]Ochsner Health, New Orleans, LA, USA; [8]Atara Biotherapeutics, South San Francisco, CA, USA; [9]Montreal Neurological Institute, McGill University, Montreal, Canada; [10]NeuroRx Research, Montreal, Canada

Presented at The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2021), October 13–15, 2021



ATA188 Phase 1 and OLE Data

AJ Joshi, MD, Senior Vice President and Chief Medical Officer

ATARA BIO®

Background

ATA188 in Progressive MS

- Many studies show that EBV infection, particularly in B cells, is strongly involved with the pathogenesis of MS[1–12]
- ATA188 is an investigational, off-the-shelf, allogeneic, T-cell immunotherapy that targets EBV-infected cells
- Sourced and produced from unrelated, EBV-seropositive, immunologically diverse donors, ATA188 is selected for each patient from an existing inventory based on an appropriate HLA restriction and allele profile (**Figure 1**)
- Here, we describe results from Part 1 of a Phase I/II study, which evaluated the safety and potential efficacy of off-the-shelf, allogeneic EBV-targeted T-cell immunotherapy (ATA188) in adults with progressive forms of MS (NCT03283826)
- Efficacy from the 12-month dose-escalation portion of this study was previously reported.[13] In summary, a higher proportion of patients showed SDI with higher doses, which was largely driven by sustained EDSS improvement

EBV = Epstein–Barr virus; EDSS = Expanded Disability Status Scale; HLA = human leukocyte antigen; MS = multiple sclerosis; SDI = sustained disability improvement.

Methods

Study Design: Details of Part 1 of this Phase I/II study design were previously reported[14]

- Patients were followed up for 1 year and could participate in a 4-year OLE
- Four cohorts received escalating doses of ATA188 to determine the recommended Part 2 dose

Endpoints: Incidence of AEs and clinically significant changes in laboratory tests, ECGs, and vital signs; identification of the recommended Part 2 dose of ATA188 (primary); and change from baseline in EDSS score

- The following were also assessed: sustained EDSS improvement (**Table 1**), sustained disability improvement (SDI; described previously[13,14]), 25-foot walk time (T25FW), and, as an exploratory endpoint, magnetization transfer ratio (MTR; assessed by MRI; **Box 1**)
- Percentage of patients with sustained EDSS improvement at 12 months is the primary endpoint of EMBOLD, the Phase II portion of this Phase I/II study

AE = adverse event; ECG = electrocardiogram; EDSS = Expanded Disability Status Scale; MRI = magnetic resonance imaging; OLE = open-label extension; SDI = sustained disability improvement.

Methods *(continued)*

Table 1. Sustained EDSS Improvement

Definition	Details
EDSS improvement	Improvement from baseline in EDSS score (minimal clinically significant improvement: –1 for baseline EDSS 3–5; –0.5 for baseline EDSS 5.5–7.0)
Sustained EDSS improvement at 6 months; 12 months	EDSS improvement at 3 months and confirmed at 6 months; EDSS improvement at 6 months and confirmed at 12 months
Sustained EDSS improvement in the OLE	EDSS improvement at any two consecutive visits (eg at 12 months and confirmed at 15 months)

Box 1. Magnetization Transfer Ratio

Changes in MTR are a marker of changes in myelin density

- An increase in MTR can reflect remyelination, and a decrease in MTR can reflect demyelination
- There is an association between MTR signal and disability change as measured by EDSS;[15] as such, **MTR may be a radiologic biomarker of EDSS improvement**

In this study, MTR was measured in two compartments:

- **Unenhancing T2 lesions** – these are mainly chronic but could include some subacute regions
- **Normal-appearing brain tissue** – this includes all tissue (white and grey matter) that is not lesion

As previously described,[13,14] SDI is defined by sustained improvements in EDSS score (as shown above) and/or T25FW (minimal clinically significant improvement –20%).
EDSS = Expanded Disability Status Scale; MTR = magnetization transfer ratio; OLE = open-label extension; SDI = sustained disability improvement; T25FW = 25-foot walk time.

Results: Patient Disposition

Figure 2. Summary of Patients Evaluated in the Part 1 Dose-escalation Portion and OLE



*In patients receiving ≥ 1 dose of ATA188; one patient who had treatment-related MS relapse 7 days after dosing in the setting of ongoing URTI symptoms and possible dental infection discontinued the study and was not evaluated for efficacy (only safety); this patient was replaced with a new patient who was evaluated for both safety and efficacy; †24 patients were evaluated for efficacy at 6 months and 23 patients were evaluated at 12 months (one patient in Cohort 3 was withdrawn, moved out of the country, and lost to 12-month follow-up); ‡In patients receiving all six doses in the initial 12-month dose-escalation portion of the study and followed up for up to 39 months as of the August 2021 data cut-off; §Patients who achieved sustained EDSS improvement either during the initial 12-month portion or in the OLE were considered sustained EDSS responders for the MTR analysis; MTR was assessed based on MRI readings taken at 6 and 12 months of the dose-escalation portion of the study.

EDSS = Expanded Disability Status Scale; MRI = magnetic resonance imaging; MS = multiple sclerosis; MTR = magnetization transfer ratio; OLE = open-label extension; SDI = sustained disability improvement; T25FW = 25-foot walk time; URTI = upper respiratory tract infection.

Efficacy: Open-label Extension

As of August 2021, OLE Data Were Available for 18 Patients Followed for up to 39 Months (Tables 2 and 3)

- 9 patients achieved SDI either during the initial 12 months or the OLE, 7 of whom did so via sustained EDSS improvement.
  - 7 patients achieved SDI during the initial 12 months, 6 of whom continued into the OLE (**Figure 2** and **Table 2**)
    - The patient with SDI in the first 12 months who did not enroll in the OLE is included in **Table 2** for completeness
  - An additional 2 patients who did not meet SDI criteria during the initial 12 months met them during the OLE
- Of the 8 patients enrolled in the OLE who achieved SDI at any point in the study (**Figure 2**), 7 maintained SDI at all subsequent time points evaluated and 1 did not (**Table 2**). The median time over which SDI was sustained in these 8 patients was 18 months (range 0.03–27.0 months).
- Patients who did not meet SDI criteria but who entered the OLE (n = 10) are shown in **Table 3**

EDSS = Expanded Disability Status Scale; OLE = open-label extension; SDI = sustained disability improvement.

Table 2. EDSS and T25FW Results Among Patients in Cohorts 1–4 Who Met SDI Criteria Within the First 12 Months and/or During the OLE*

Clinically significant improvement | Trend for improvement/stable | Clinically significant decline | Trend for decline | Redosed for OLE Year 2 – Cohort 3 dose | Redosed for OLE Year 3 – Cohort 3 dose

Cohort	Patient	SDI First Achieved	SDI based on EDSS and/or T25FW	Scale	Baseline	3 months	6 months	12 months	15 months	18 months	21 months	24 months	27 months	30 months	33 months
1 (5×10^6 cells)	A (101-003)	6 months	EDSS	EDSS score	4.5	3.0	3.0	3.0	Patient A did not enroll in OLE						
				ΔT25FW	–	–3.0%	+15.2%	–3.0%							
	H (103-001)†	24 months	EDSS, T25FW	EDSS score	5.5	5.5	5.5	5.5	–	–	5.0	5.0	3.5	3.0	3.5
				ΔT25FW	–	–11.0%	–21.5%	–19.2%	–	–	–30.8%	–41.3%	–38.4%	–39.0%	–27.3%
2 (1×10^7 cells)	B (103-010)	6 months	T25FW	EDSS score	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0	–	6.0
				ΔT25FW	–	–21.1%	–37.2%	–37.8%	–31.7%	–30.0%	–29.4%	–30.0%	–37.8%	–	–36.1%
3 (2×10^7 cells)	C (101-004)	12 months	EDSS	EDSS score	6.0	6.0	5.0	5.0	5.0	5.0	4.5	4.5	4.5	–	–
				ΔT25FW	–	–8.2%	–10.2%	–	–17.7%	–7.5%	–8.2%	–16.3%	–20.4%	–	–
	D (103-007)	6 months	T25FW	EDSS score	6.0	6.0	6.0	6.0	6.0	6.0	6.0	6.0	–	–	–
				ΔT25FW	–	–34.8%	–40.9%	–58.2%	–49.0%	–58.4%	–46.0%	–44.0%	–	–	–
	E (103-008)	6 months	EDSS	EDSS score	5.5	3.5	3.5	3.5	3.0	4.0	3.0	4.5	–	3.0	–
				ΔT25FW	–	–10.8%	–13.3%	–0.8%	–19.2%	–3.3%	–5.8%	–6.7%	–	–5.8%	–
4 (4×10^7 cells)	F (210-001)	6 months	EDSS	EDSS score	6.5	6.0	6.0	6.0	6.0	6.0	6.0	6.0	–	–	–
				ΔT25FW	–	–0.9%	–11.1%	–3.5%	+52.5%	+2.8%	+19.3%	+80.1%	–	–	–
	G (210-003)	6 months	EDSS	EDSS score	6.0	5.5	5.0	4.5	5.0	4.5	4.5	4.5	–	–	–
				ΔT25FW	–	+14.5%	–8.1%	–16.1%	–8.1%	–9.7%	–5.6%	–17.7%	–	–	–
	K (210-006)	15 months	EDSS	EDSS score	5.5	5.5	5.5	4.5	4.5	5.5	Patient K had a relapse at 18 months and decided to discontinue the study to try an alternative therapy				
				ΔT25FW	–	+15.2%	–12.9%	+17.4%	+9.1%	+8.3%					

Minimal clinically significant improvement: EDSS score –1 for baseline EDSS 3–5, –0.5 for baseline EDSS 5.5–7.0; T25FWT –20%. Clinically significant decline is defined as the same magnitude as improvement but in the opposite direction. *Columns for 36 months and 39 months are not shown as there are no data available for the patients who achieved SDI as of August 2021 at these timepoints. †Following the 12-month assessment, the patient had a treatment gap before redosing for the OLE and did not undergo any scheduled assessments during the interim period.

EDSS = Expanded Disability Status Scale; OLE = open-label extension; SDI = sustained disability improvement; T25FW = 25-foot walk time; ΔT25FW = change in T25FW from baseline.

Table 3. EDSS and T25FW Results Among Patients in Cohorts 1–4 with OLE Data – Patients Without SDI

Clinically significant improvement | Trend for improvement/stable | Clinically significant decline | Trend for decline | Redosed for OLE Year 2 – Cohort 3 dose | Redosed for OLE Year 3 – Cohort 3 dose

Cohort	Patient	Scale	Baseline	3 months	6 months	12 months	15 months	18 months	21 months	24 months	27 months	30 months	33 months	36 months	39 months
1 (5×10^6 cells)	P (101-005)*	EDSS score	6.0	6.0	6.0	6.0	–	–	–	–	6.0	6.0	6.0	6.0	–
		ΔT25FW	–	+16.7%	+16.7%	+45.8%	–	–	–	–	+30.0%	+21.7%	+41.7%	+21.7%	+57.5%
	Q (101-006)*	EDSS score	6.0	6.0	6.0	6.0	–	–	–	–	–	6.0	6.0	6.0	6.0
		ΔT25FW	–	+28.3%	+12.4%	+53.1%	–	–	–	–	–	+123.4%	+234.5%	+200.7%	+185.5%
2 (1×10^7 cells)	L (201-003)*	EDSS score	4.0	4.0	4.0	4.0	–	4.0	4.0	4.0	3.5	3.5	–	–	–
		ΔT25FW	–	–20.5%	–19.9%	–17.2%	–	–12.6%	–14.6%	–21.2%	–17.9%	–12.6%	–	–	–
	S (101-008)*	EDSS score	6.5	6.5	6.5	6.5	–	–	–	–	7.5	7.5	7.5	–	–
		ΔT25FW	–	–20.1%	+3.6%	+94.4%	–	–	–	–	–†	–†	–†	–	–
	R (102-002)*	EDSS score	6.5	6.5	6.5	6.5	–	–	6.5	6.5	6.5	–	–	–	–
		ΔT25FW	–	+30.7%	+59.0%	+65.1%	–	–	+177.7%	+413.9%	+379.5%	–	–	–	–
3 (2×10^7 cells)	I (101-002)	EDSS score	6.5	6.5	6.5	6.5	6.0	6.5	6.5	6.5	–	–	–	–	–
		ΔT25FW	–	+19.3%	+43.9%	+24.7%	+47.5%	+48.0%	+13.5%	+63.7%	–	–	–	–	–
	J (103-006)	EDSS score	4.5	4.5	6.0	6.0	6.0	6.0	6.0	6.0	–	–	–	–	–
		ΔT25FW	–	–5.3%	–12.8%	+22.6%	+9.0%	–15.0%	–15.0%	–11.3%	–	–	–	–	–
4 (4×10^7 cells)	M (101-011)	EDSS score	6.0	6.0	6.0	6.0	6.0	6.0	6.5	6.0	–	–	–	–	–
		ΔT25FW	–	+24.4%	+10.7%	–7.6%	+9.6%	+16.8%	+24.9%	+18.8%	–	–	–	–	–
	N (102-004)	EDSS score	6.0	6.0	6.0	6.5	7.0	7.0	6.0	7.5	–	–	–	–	–
		ΔT25FW	–	+3.4%	+31.2%	+65.4%	–†	–†	–†	–†	–	–	–	–	–
	O (210-002)	EDSS score	6.0	5.5	6.0	6.0	6.0	6.0	6.0	6.0	–	–	–	–	–
		ΔT25FW	–	+2.9%	–3.3%	–21.9%	+31.4%	+0.8%	0.0%	+21.1%	–	–	–	–	–

Minimal clinically significant improvement: EDSS score –1 for baseline EDSS 3–5, –0.5 for baseline EDSS 5.5–7.0; T25FWT –20%. Clinically significant decline is defined as the same magnitude as improvement but in the opposite direction. *Following the 12-month assessment, the patient had a treatment gap before redosing for the OLE and did not undergo any scheduled assessments during the interim period; †Patient was unable to complete the test at this time point because of physical limitations; therefore, the result was recorded as 'decline' with no associated numerical value.

EDSS = Expanded Disability Status Scale; OLE = open-label extension; SDI = sustained disability improvement; T25FW = 25-foot walk time; ΔT25FW = change in T25FW from baseline.

Safety

25 Patients Received ≥ 1 Dose of ATA188 and Were Evaluated for Safety

As of August 2021, inclusive of the OLE, in which patients were followed up for up to 39 months:

- No Grade > 3 events, dose-limiting toxicities, cytokine-release syndrome, or graft-versus-host disease were observed
- Three treatment-emergent SAEs were reported, as follows:
  - One patient in Cohort 4 had a Grade 3 SAE of MS relapse, reported as possibly related to treatment, 7 days after dosing in the setting of ongoing URTI symptoms and possible dental infection
  - One patient in Cohort 3 had a Grade 2 SAE of muscle spasticity, reported as unrelated to treatment
  - One patient in Cohort 4 had a Grade 2 SAE of fall, reported as unrelated to treatment [occurred during OLE]

MS = multiple sclerosis; OLE = open-label extension; SAE = serious adverse event; URTI = upper respiratory tract infection.



New Magnetization Transfer Ratio Imaging Data from a Phase I Study of ATA188, an Off-the-shelf, Allogeneic Epstein–Barr Virus Targeted T-cell Immunotherapy for Progressive Multiple Sclerosis

Douglas L. Arnold, MD, Montreal Neurological Institute,
McGill University and NeuroRx Research, Montreal, Canada

Magnetization Transfer Ratio

Changes in MTR are a marker of changes in myelin density

- An increase in MTR can reflect remyelination, and a decrease in MTR can reflect demyelination
- There is an association between MTR signal and disability change as measured by EDSS;[15] as such, **MTR may be a radiologic biomarker of EDSS improvement**

In this study, MTR was measured in two compartments:

- **Unenhancing T2 lesions** – these are mainly chronic but could include some subacute regions
- **Normal-appearing brain tissue** – this includes all tissue (white and grey matter) that is not lesion

As previously described,[13,14] SDI is defined by sustained improvements in EDSS score (as shown above) and/or T25FW (minimal clinically significant improvement –20%).
EDSS = Expanded Disability Status Scale; MTR = magnetization transfer ratio; OLE = open-label extension; SDI = sustained disability improvement; T25FW = 25-foot walk time.

Efficacy: Magnetization Transfer Ratio

Changes in MTR from Baseline for Unenhancing T2 Lesions and Normal-appearing Brain Tissue Were Assessed at 6 and 12 Months in Patients Who Achieved Sustained EDSS Improvement at Any Point in The Study Versus Those Who Did Not (Figure 3)

- Patients achieving sustained EDSS improvement at any time (versus those who did not):
  - Showed a significant increase from baseline in MTR for unenhancing T2 lesions at 12-months (**Figure 3B**)
  - Showed a greater increase from baseline in MTR for unenhancing T2 lesions at 6-months (**Figure 3A**)
  - Showed a greater increase from baseline in MTR for normal-appearing brain tissue at 12-months (**Figures 3D**)
  - This trend appeared to occur in patients with either PPMS or SPMS (**Figures 3A, 3B and 3D**)
- Compared to baseline, MTR at 12 months for unenhanced T2 lesions and normal-appearing brain tissue in patients with sustained EDSS improvement increased (median change of 0.134 and 0.082, respectively), whereas MTR in those patients without sustained EDSS improvement remained unchanged (median change of –0.030 and 0.005, respectively).
- In general, a trend supporting a relationship between improvement in MTR signal and decrease in EDSS score (improvement in disability) was observed (**Figure 4**)

EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; MTR = magnetization transfer ratio; PPMS = primary progressive MS; SPMS = secondary progressive MS.

Figure 3. MTR at 6 and 12 Months in Patients Achieving and Not Achieving Sustained EDSS Improvement at Any Time (Including OLE)*



*Some imaging scans could not be obtained or were unreadable; †Patient 102-002 (PPMS) with change in MTR for unenhancing T2 lesions of 0.506 at 12 months was excluded from the plot because of the scale limit of the y-axis.

EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; MTR = magnetization transfer ratio; OLE = open-label extension; PPMS = primary progressive MS; SPMS = secondary progressive MS.

Figure 4. MTR Versus EDSS Score at 6 and 12 Months*

MTR for Unenhancing T2 Lesions

MTR for Normal-appearing Brain Tissue



*Some imaging scans could not be obtained or were unreadable.

EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; MTR = magnetization transfer ratio; PPMS = primary progressive MS; SPMS = secondary progressive MS.

Conclusions

- **Updated OLE results in patients with progressive forms of MS treated with ATA188 followed for up to 39 months, as well as new magnetization transfer ratio data showed the following:**
  - **Sustained clinical benefit:** 7 of the 8 patients who enrolled in the OLE and achieved SDI at any time point maintained SDI at all future time points. In the majority, SDI was driven by sustained EDSS improvement.
  - **Evidence of possible remyelination:** Patients who achieved sustained EDSS improvement at any time in the study (versus those who did not) showed greater increases in MTR from baseline at 12 months, which may be suggestive of remyelination. In general, an increase in MTR was associated with improvement in EDSS scores.
  - **Safety and tolerability:** Preliminary data suggest that ATA188 is safe and well tolerated.

EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; MTR = magnetization transfer ratio; OLE = open-label extension; SDI = sustained disability improvement.

Conclusions *(continued)*

- **These data suggest that following ATA188 treatment, patients may achieve SDI, and specifically sustained EDSS improvement, at a higher rate and longer duration than would be expected based on the natural history of progressive MS.**
- **The MTR data provide evidence that structural changes suggestive of remyelination may be driving such prolonged sustained improvement.**
- **Although encouraging, these results need to be confirmed within a randomized, placebo-controlled study.**

The Phase II RCT Portion of This Study, EMBOLD (NCT03283826), is Ongoing and Currently Enrolling

EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; MTR = magnetization transfer ratio; RCT = randomized controlled trial; SDI = sustained disability improvement.



Clinician Perspective

Gavin Giovannoni, MBBCh, Ph.D., Centre for Neuroscience and Trauma, Barts and The London School of Medicine and Dentistry, London, England

ATARA BIO®



ATA188 Phase 1 and OLE Data Summary

AJ Joshi, MD, Senior Vice President and Chief Medical Officer

ATARA BIO®

In the Phase 1 and OLE, Treatment with ATA188 Led to Sustained EDSS Improvement in Some Patients Suggesting a Possible Reversal of Disease Progression



ATARA BIO®

Note: Chart is not to scale and does not accurately depict time to progression from one to stage to another. EDSS 0 (not shown) represents normal neurological exam; EDSS 1-2 represent minimal disability. EDSS scores 8-10 (not shown) represent progression to bed rest and death. Time to progression on EDSS varies significantly from patient to patient. Graphic based on: 1) Kurtzke JF. *Neurology*. 1983;33:1444-1452; 2) Kurtzke Expanded Disability Status Scale description *Patient A did not enroll in OLE; **Patient K had a relapse at 18 months, reverted to 5.5 EDSS, and decided to discontinue the study.

Figure 3. MTR at 6 and 12 Months in Patients Achieving and Not Achieving Sustained EDSS Improvement at Any Time (Including OLE)*



*Some imaging scans could not be obtained or were unreadable; †Patient 102-002 (PPMS) with change in MTR for unenhancing T2 lesions of 0.506 at 12 months was excluded from the plot because of the scale limit of the y-axis.

EDSS = Expanded Disability Status Scale; MS = multiple sclerosis; MTR = magnetization transfer ratio; OLE = open-label extension; PPMS = primary progressive MS; SPMS = secondary progressive MS.

Summary of Data and Findings

- Updated results from the ongoing OLE demonstrate continued safety and tolerability of ATA188 with the longest observed patients receiving up to 3 annual retreatments and up to 39 months of follow up
- SDI with ATA188 was driven by sustained EDSS improvement in most patients, disability improvement was maintained at all subsequent timepoints in all but one patient
- Patients treated with ATA188 may achieve SDI, and specifically sustained EDSS improvement, at a higher rate and longer duration than would be expected based on the natural history of progressive MS
- Patients who achieved sustained EDSS improvement with ATA188 at any time in the study (versus those who did not) showed greater increases in MTR from baseline at 12 months, which may be suggestive of remyelination. In general, an increase in MTR was associated with improvement in EDSS scores
- MTR data provide evidence that suggest remyelination may be biological basis for clinical disability improvements observed with ATA188
- A total of 25 patients enrolled in the Ph 1a study (initial 12 mo), 18 of whom continued into the OLE
  - Nine patients met SDI criteria either in the initial 12-month period (n=7) or in the OLE (n=2) and of these, seven patients had sustained EDSS improvement
  - 11 patients remained stable throughout their participation in the study (4 through the initial 12 month period and 7 through the OLE)
  - 4 patients had confirmed disability progression either in the initial 12 month period (n=1) or in the OLE (n=3)



Upcoming ATA188 Events: Driving Towards Potential Value of a Transformative Therapy

Pascal Touchon, President and Chief Executive Officer

ATARA BIO®

Summary and Next Steps for ATA188

ATA188
Potential transformative therapy in progressive MS with multi-billion dollar revenue opportunity
Demonstrated each element of our manufacturing platform to support a biologics-like COGM at commercial scale
Phase 2 EMBOLD study ongoing and enrollment is progressing well
Interim Analysis planned for H1 2022
Ongoing discussions with large pharma partners are generating high level of interest

ATARA BIO®

ATARA BIO®

Thank You

Patients and families

Investigators and support teams

Our collaborators at QIMR

Investors and analyst community

Atara staff

Nasdaq: ATRA